Chemotherapy combined with high-dose extended-field radiotherapy for stage I extranodal nasal-type natural killer/T-cell lymphoma

• Main Authors: Luo J, Cao C, Zhu Y, Liu P, Liu L, Lu K, Zhang N, Zhou N
• Format: Article
• Language: English
• Published: Dove Medical Press 2016-10-01
• Series: OncoTargets and Therapy
• Subjects: Natural killer/T-cell lymphoma; chemotherapy; radiotherapy; prognosis
• Online Access: https://www.dovepress.com/chemotherapy--combined-with-high-dose-extended-field-radiotherapy-for--peer-reviewed-article-OTT

Jialin Luo,* Caineng Cao,* Yuan Zhu, Peng Liu, Luying Liu, Ke Lu, Na Zhang, Ning Zhou Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation Oncology, Hangzhou, People’s Republic of China *These authors contributed equally to this work Background and objective: The objective of the study was to evaluate the efficiency of chemotherapy (CT) combined with high-dose extended-field radiotherapy (RT) in stage I extranodal nasal-type natural killer/T-cell lymphoma (NKTCL). Patients and methods: Between January 2001 and November 2010, 103 stage I extranodal nasal-type NKTCL patients were retrospectively analyzed. Of these patients, 75 patients were treated by RT plus CT and 28 patients were treated by RT alone. CT included cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or CHOP-like regimen. Results: The median follow-up time was 42.6 months (range, 7.4–126.7 months). For patients in the RT alone group, the 5-year estimated progression-free survival (PFS) and overall survival (OS) rates were 67.0% and 71.4%, respectively. For patients in the RT + CT group, the 5-year estimated PFS and OS rates were 69.0% and 63.7%, respectively. In multivariate analysis, CT was an independent factor for PFS. Conclusion: The doxorubicin-based CT combined with high-dose extended-field RT yielded promising outcomes for stage I extranodal nasal-type NKTCL, and CT was an independent factor for PFS. Keywords: natural killer/T-cell lymphoma, chemotherapy, radiotherapy, prognosis